What is Generate Biomedicines, Inc. 's stock-based comp?

Generate Biomedicines, Inc. (GENB) reported stock-based comp of $6.4M in Q1 2026.

What does stock-based comp mean?

Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.

Generate Biomedicines, Inc. GENB Stock-Based Comp

Stock-Based Comp at other companies

MYR GroupMYRG

$3.39M+45.1%

Macy'sM

$14M+7.7%

Moelis & CompanyMC

$72.21M-16.3%

BalchemBCPC

$5.36M+40.6%

Alignment HealthcareALHC

$14.02M-18.4%

Sabra HealthcareSBRA

$3.1M+14.3%

Other financials

Income statement

See full

Revenue$7.2M-18.1%

Operating income-$64.1M-33.1%

Net income-$61.4M-47.4%

EPS (diluted)-$1.07+34.0%

Balance sheet

See full

Cash & equivalents$160.6M-27.2%

Total debt$65.6M—

Total equity$514.8M+209%

Total assets$625.7M—

Cash flow

See full

Operating cash flow-$80.4M-51.2%

CapEx$3.8M+403%

Free cash flow-$84.2M-56.1%

Valuation

See full

Market cap$1.86B—

Enterprise value$1.76B—

Returns & leverage

See full

Debt / equity0.1×—

Current ratio9.2×—

Where this comes from

Reported directly by Generate Biomedicines, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: Generate Biomedicines, Inc. ’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Generate Biomedicines, Inc. 's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Generate Biomedicines, Inc. 's stock-based comp?: Generate Biomedicines, Inc. (GENB) reported stock-based comp of $6.4M in Q1 2026.
What does stock-based comp mean?: Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.